94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1544682
This article is part of the Research TopicExploring Small Molecule Probes: Advancements and Applications in Pharmacological ResearchView all 4 articles
The development of a high-throughput acoustic droplet ejection massspectrometry assay and a solid-supported membrane (SSM)-based electrophysiological assay to study the pharmacological inhibition of SLC1-A3, -A2 and -A1 in a drug discovery program
Provisionally accepted- Sanofi (Germany), Frankfurt, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The solute carrier (SLC) family comprises a diverse group of membrane proteins essential for transporting a variety of substrates across cellular membranes. In this manuscript, we are presenting the development of assays pertinent to drug discovery, with particular emphasis on the SLC1 family members: SLC1A3 (EAAT1), SLC1A2 (EAAT2), and SLC1A1 (EAAT3). Utilizing advanced methodologies such as Acoustic Droplet Ejection Mass Spectrometry (ADE-MS) and Solid Supported Membrane (SSM)-based electrophysiology, we endeavor to establish robust assays that can facilitate future drug discovery campaigns.
Keywords: Drug Discovery, excitatory amino acid transporters (EAATs), high content screening, acoustic droplet ejection mass-spectrometry, SSM-based electrophysiology
Received: 13 Dec 2024; Accepted: 17 Mar 2025.
Copyright: © 2025 Bärenz, Zuschlag, Pommereau, Warkentin and Licher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Felix Bärenz, Sanofi (Germany), Frankfurt, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.